Background: The role of bronchodilators in the treatment of bronchiolitis remains controversial. M e t M : A double-blind, placebo controlled trial was performed to evaluate the clinical response to nebulized salbutamol. One hundred and fifty-six infants aged between 7 weeks and 24 months who had had an episode of wheezing and other signs and symptoms of bronchiolitis were randomized to three groups as follows: (i) nebulized salbutamol was administered to 52 patients in group I at a dose of 0.15 mgkg in 2 mL saline: (ii) saline was nebulized to 52 patients in group I1 and (iii) in group 111 52 patients received mist in a tent. All three groups were administered oxygen during the procedures. Treatment was repeated with the same agent after 30 min if the respiratory score was 5 or more. Respiratory rate, heart rate, oxygen saturation and presence of cyanosis, wheezing, retractions were recorded before and after each treatment. Results:The decrease in the respiratory score was 5.2 * 1.8, 0.82 * 2.4 and 1.7 1.3 in group I, I1 and 111, respectively. The decrease in group I was significantly higher than in the other groups. Heart rate was similar between groups. Oxygen saturation decreased in group I without reaching statistical significance. Comluswns:Salbutamol was shown to be effective and safe in the treatment of acute bronchiolitis. , 1 8 October 1997. recorded. A second dose of each-medication was given to Salbutamol in bronchiolitis 253 patients with a RDS greater than 5 at 30 min. Heart rate, S,o, and RDS were recorded again at the end of the first hour and the study was completed. Statistical analysis was performed by Student's t-test, Chi-squared and ANOVA analysis.

Midazolam is effective and safe in the control of refractory generalized convulsive SE. The response to treatment and mortality were related to the underlying aetiology.